Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Practical lipid management [[electronic resource] ] : concepts and controversies / / Peter P. Toth, Kevin C. Maki
| Practical lipid management [[electronic resource] ] : concepts and controversies / / Peter P. Toth, Kevin C. Maki |
| Autore | Toth Peter P |
| Pubbl/distr/stampa | Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 |
| Descrizione fisica | 1 online resource (264 p.) |
| Disciplina |
616.3/997
616.3997 |
| Altri autori (Persone) | MakiKevin C |
| Soggetto topico |
Hyperlipidemia - Treatment
Coronary heart disease - Prevention |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-93939-0
9786611939397 0-470-69687-7 0-470-69688-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Practical Lipid Management; Contents; Foreword; Preface; Acknowledgements; Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview; 1.1 Early History of Cardiovascular Epidemiology; 1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention; 1.3 LDL-C and CHD Risk; 1.4 LDL-C Lowering and CHD Risk Reduction; 1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants; 1.6 HDL-C and CHD Risk; 1.7 Trends in Lipids and Lipid Management in the USA
1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II SurveyControversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?; Chapter 2 Vascular Biology and Atherogenesis; 2.1 Introduction; 2.2 Arterial Structure; 2.3 Endothelial Cell Function and Dysfunction; 2.4 The Role of Monocytes and Lymphocytes; 2.5 Atheromatous Plaques; Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults 3.1 Matching Aggressiveness of Treatment to Absolute Risk3.2 Screening for Dyslipidemias; 3.3 Risk Stratification; 3.4 Steps in the Risk Stratification Process - Major Risk Categories; 3.5 Tips for Calculating the Framingham Risk Score; 3.6 Subcategories for Consideration of More Aggressive Optional Treatment Goals; 3.7 Very High Risk Patients, Optional LDL-C Goal <70 mg dl-1; 3.8 Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl-1; 3.9 Treatment Goals for Patients with Elevated Triglycerides; 3.10 Triglycerides and HDL-C as Targets for Therapy Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?Chapter 4 Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome; 4.1 Nature and Nurture in the Development of CHD Risk Factors; 4.2 Lifestyle Factors as Determinants of CHD Risk in Populations; 4.3 Within Country Variations in Lifestyle and CHD Risk; 4.4 The Metabolic Syndrome; 4.5 Therapeutic Lifestyle Changes; 4.6 The TLC Diet; 4.7 Dietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products; 4.8 Physical Activity and Weight Reduction 4.9 Smoking Cessation4.10 Importance of Allied Health Professionals; Chapter 5 Management of Elevated Low-Density Lipoprotein Cholesterol; 5.1 Relationship between LDL-C and Risk for Cardiovascular Events; 5.2 Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk; 5.3 Genetic Disorders Associated with Elevated LDL-C; 5.4 Atherogenic Impact of LDL-C; 5.5 Management of Elevated LDL-C; 5.6 Summary; Controversy: How Low Should We Go?; Controversy: Risks and Bene.ts of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on "How Low You Go" or also on "How You Get There"? |
| Record Nr. | UNINA-9910144106903321 |
Toth Peter P
|
||
| Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Practical lipid management [[electronic resource] ] : concepts and controversies / / Peter P. Toth, Kevin C. Maki
| Practical lipid management [[electronic resource] ] : concepts and controversies / / Peter P. Toth, Kevin C. Maki |
| Autore | Toth Peter P |
| Pubbl/distr/stampa | Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 |
| Descrizione fisica | 1 online resource (264 p.) |
| Disciplina |
616.3/997
616.3997 |
| Altri autori (Persone) | MakiKevin C |
| Soggetto topico |
Hyperlipidemia - Treatment
Coronary heart disease - Prevention |
| ISBN |
1-281-93939-0
9786611939397 0-470-69687-7 0-470-69688-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Practical Lipid Management; Contents; Foreword; Preface; Acknowledgements; Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview; 1.1 Early History of Cardiovascular Epidemiology; 1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention; 1.3 LDL-C and CHD Risk; 1.4 LDL-C Lowering and CHD Risk Reduction; 1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants; 1.6 HDL-C and CHD Risk; 1.7 Trends in Lipids and Lipid Management in the USA
1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II SurveyControversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?; Chapter 2 Vascular Biology and Atherogenesis; 2.1 Introduction; 2.2 Arterial Structure; 2.3 Endothelial Cell Function and Dysfunction; 2.4 The Role of Monocytes and Lymphocytes; 2.5 Atheromatous Plaques; Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults 3.1 Matching Aggressiveness of Treatment to Absolute Risk3.2 Screening for Dyslipidemias; 3.3 Risk Stratification; 3.4 Steps in the Risk Stratification Process - Major Risk Categories; 3.5 Tips for Calculating the Framingham Risk Score; 3.6 Subcategories for Consideration of More Aggressive Optional Treatment Goals; 3.7 Very High Risk Patients, Optional LDL-C Goal <70 mg dl-1; 3.8 Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl-1; 3.9 Treatment Goals for Patients with Elevated Triglycerides; 3.10 Triglycerides and HDL-C as Targets for Therapy Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?Chapter 4 Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome; 4.1 Nature and Nurture in the Development of CHD Risk Factors; 4.2 Lifestyle Factors as Determinants of CHD Risk in Populations; 4.3 Within Country Variations in Lifestyle and CHD Risk; 4.4 The Metabolic Syndrome; 4.5 Therapeutic Lifestyle Changes; 4.6 The TLC Diet; 4.7 Dietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products; 4.8 Physical Activity and Weight Reduction 4.9 Smoking Cessation4.10 Importance of Allied Health Professionals; Chapter 5 Management of Elevated Low-Density Lipoprotein Cholesterol; 5.1 Relationship between LDL-C and Risk for Cardiovascular Events; 5.2 Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk; 5.3 Genetic Disorders Associated with Elevated LDL-C; 5.4 Atherogenic Impact of LDL-C; 5.5 Management of Elevated LDL-C; 5.6 Summary; Controversy: How Low Should We Go?; Controversy: Risks and Bene.ts of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on "How Low You Go" or also on "How You Get There"? |
| Record Nr. | UNINA-9910831085403321 |
|
Toth Peter P
|
||
| Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Practical lipid management [[electronic resource] ] : concepts and controversies / / Peter P. Toth, Kevin C. Maki
| Practical lipid management [[electronic resource] ] : concepts and controversies / / Peter P. Toth, Kevin C. Maki |
| Autore | Toth Peter P |
| Pubbl/distr/stampa | Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 |
| Descrizione fisica | 1 online resource (264 p.) |
| Disciplina |
616.3/997
616.3997 |
| Altri autori (Persone) | MakiKevin C |
| Soggetto topico |
Hyperlipidemia - Treatment
Coronary heart disease - Prevention |
| ISBN |
1-281-93939-0
9786611939397 0-470-69687-7 0-470-69688-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Practical Lipid Management; Contents; Foreword; Preface; Acknowledgements; Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview; 1.1 Early History of Cardiovascular Epidemiology; 1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention; 1.3 LDL-C and CHD Risk; 1.4 LDL-C Lowering and CHD Risk Reduction; 1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants; 1.6 HDL-C and CHD Risk; 1.7 Trends in Lipids and Lipid Management in the USA
1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II SurveyControversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?; Chapter 2 Vascular Biology and Atherogenesis; 2.1 Introduction; 2.2 Arterial Structure; 2.3 Endothelial Cell Function and Dysfunction; 2.4 The Role of Monocytes and Lymphocytes; 2.5 Atheromatous Plaques; Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults 3.1 Matching Aggressiveness of Treatment to Absolute Risk3.2 Screening for Dyslipidemias; 3.3 Risk Stratification; 3.4 Steps in the Risk Stratification Process - Major Risk Categories; 3.5 Tips for Calculating the Framingham Risk Score; 3.6 Subcategories for Consideration of More Aggressive Optional Treatment Goals; 3.7 Very High Risk Patients, Optional LDL-C Goal <70 mg dl-1; 3.8 Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl-1; 3.9 Treatment Goals for Patients with Elevated Triglycerides; 3.10 Triglycerides and HDL-C as Targets for Therapy Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?Chapter 4 Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome; 4.1 Nature and Nurture in the Development of CHD Risk Factors; 4.2 Lifestyle Factors as Determinants of CHD Risk in Populations; 4.3 Within Country Variations in Lifestyle and CHD Risk; 4.4 The Metabolic Syndrome; 4.5 Therapeutic Lifestyle Changes; 4.6 The TLC Diet; 4.7 Dietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products; 4.8 Physical Activity and Weight Reduction 4.9 Smoking Cessation4.10 Importance of Allied Health Professionals; Chapter 5 Management of Elevated Low-Density Lipoprotein Cholesterol; 5.1 Relationship between LDL-C and Risk for Cardiovascular Events; 5.2 Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk; 5.3 Genetic Disorders Associated with Elevated LDL-C; 5.4 Atherogenic Impact of LDL-C; 5.5 Management of Elevated LDL-C; 5.6 Summary; Controversy: How Low Should We Go?; Controversy: Risks and Bene.ts of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on "How Low You Go" or also on "How You Get There"? |
| Record Nr. | UNINA-9910841471503321 |
|
Toth Peter P
|
||
| Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||